论文信息 - Phase 1 dose-escalation study of BI 836909, an anti-BCMA bi-specific T-cell engager, in relapsed and/or refractory multiple myeloma (RRMM). - 字舞流文

Phase 1 dose-escalation study of BI 836909, an anti-BCMA bi-specific T-cell engager, in relapsed and/or refractory multiple myeloma (RRMM).

H. Einsele | P. Moreau | C. Langer | G. Zugmaier | T. Facon | M. Attal | C. Gomez-Roca | G. Munzert | M. Topp | E. Gracien | B. Hébraud | J. Düll